Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Carrier

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The American Journal of Pathology|April 13, 2013
Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreasTalal Al Saati, Pascal Clerc, Naïma Hanoun, et al.
Antioxidants & Redox Signaling|January 18, 2011
Absence of tumor suppressor tumor protein 53-induced nuclear protein 1 (TP53INP1) sensitizes mouse thymocytes and embryonic fibroblasts to redox-driven apoptosisPrudence N'guessan, Laurent Pouyet, Gaëlle Gosset, et al.
Cancer Research|July 5, 2017
TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular CarcinomaKai-Yu Ng, Lok-Hei Chan, Stella Chai, et al.
Cancer Research|January 2, 2009
Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant functionCarla E Cano, Julien Gommeaux, Sylvia Pietri, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 27, 2019
PML hyposumoylation is responsible for the resistance of pancreatic cancerMirna Swayden, George Alzeeb, Rawand Masoud, et al.
Iscience|June 12, 2023
Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression <i>in vivo</i>Gabriela Reyes-Castellanos, Nadine Abdel Hadi, Scarlett Gallardo-Arriaga, et al.
Cell Reports. Medicine|December 9, 2020
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic CancerRawand Masoud, Gabriela Reyes-Castellanos, Sophie Lac, et al.
The FEBS Journal|November 24, 2021
Meeting report of the 4th biennial Metabolism and Cancer symposiumNadine Abdel Hadi, Emeline Boet, Airelle Lahalle, et al.
EMBO Molecular Medicine|April 2, 2015
Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1Marion Seillier, Laurent Pouyet, Prudence N'Guessan, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The American Journal of Pathology|April 13, 2013
Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreasTalal Al Saati, Pascal Clerc, Naïma Hanoun, et al.
Antioxidants & Redox Signaling|January 18, 2011
Absence of tumor suppressor tumor protein 53-induced nuclear protein 1 (TP53INP1) sensitizes mouse thymocytes and embryonic fibroblasts to redox-driven apoptosisPrudence N'guessan, Laurent Pouyet, Gaëlle Gosset, et al.
Cancer Research|July 5, 2017
TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular CarcinomaKai-Yu Ng, Lok-Hei Chan, Stella Chai, et al.
Cancer Research|January 2, 2009
Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant functionCarla E Cano, Julien Gommeaux, Sylvia Pietri, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 27, 2019
PML hyposumoylation is responsible for the resistance of pancreatic cancerMirna Swayden, George Alzeeb, Rawand Masoud, et al.
Iscience|June 12, 2023
Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression <i>in vivo</i>Gabriela Reyes-Castellanos, Nadine Abdel Hadi, Scarlett Gallardo-Arriaga, et al.
Cell Reports. Medicine|December 9, 2020
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic CancerRawand Masoud, Gabriela Reyes-Castellanos, Sophie Lac, et al.
The FEBS Journal|November 24, 2021
Meeting report of the 4th biennial Metabolism and Cancer symposiumNadine Abdel Hadi, Emeline Boet, Airelle Lahalle, et al.
EMBO Molecular Medicine|April 2, 2015
Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1Marion Seillier, Laurent Pouyet, Prudence N'Guessan, et al.
Pageof 5